Free Trial

Physiomics (PYC) Competitors

Physiomics logo
GBX 0.43 +0.00 (+0.47%)
As of 03:53 AM Eastern

PYC vs. MTFB, DEST, ROQ, VAL, RENE, NFX, SALV, ONC, OVB, and OCTP

Should you be buying Physiomics stock or one of its competitors? The main competitors of Physiomics include Motif Bio (MTFB), Destiny Pharma (DEST), Roquefort Therapeutics (ROQ), ValiRx (VAL), ReNeuron Group (RENE), Nuformix (NFX), SalvaRx Group (SALV), Oncimmune (ONC), Ovoca Bio (OVB), and Oxford Cannabinoid Technologies (OCTP). These companies are all part of the "biotechnology" industry.

Physiomics vs.

Physiomics (LON:PYC) and Motif Bio (LON:MTFB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment, community ranking and earnings.

Motif Bio has lower revenue, but higher earnings than Physiomics. Physiomics is trading at a lower price-to-earnings ratio than Motif Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Physiomics£864.07K1.01-£922.82K-£0.45-0.96
Motif BioN/AN/AN/A-£19.20N/A

In the previous week, Physiomics' average media sentiment score of 0.00 equaled Motif Bio'saverage media sentiment score.

Company Overall Sentiment
Physiomics Neutral
Motif Bio Neutral

Motif Bio received 289 more outperform votes than Physiomics when rated by MarketBeat users. Likewise, 74.40% of users gave Motif Bio an outperform vote while only 55.56% of users gave Physiomics an outperform vote.

CompanyUnderperformOutperform
PhysiomicsOutperform Votes
80
55.56%
Underperform Votes
64
44.44%
Motif BioOutperform Votes
369
74.40%
Underperform Votes
127
25.60%

Motif Bio has a net margin of 0.00% compared to Physiomics' net margin of -106.80%. Motif Bio's return on equity of 0.00% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Physiomics-106.80% -127.68% -76.38%
Motif Bio N/A N/A N/A

Summary

Motif Bio beats Physiomics on 6 of the 8 factors compared between the two stocks.

Get Physiomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

PYC vs. The Competition

MetricPhysiomicsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£876,000.00£125.35M£5.53B£2.59B
Dividend Yield6.20%3.69%5.11%4.97%
P/E Ratio-0.963.2622.59133.72
Price / Sales1.014,337.35401.35232,158.79
Price / Cash4.2113.0238.1828.12
Price / Book2.0534.506.774.58
Net Income-£922,817.80-£90.45M£3.22B£5.84B
7 Day Performance-4.90%1.75%1.39%2.88%
1 Month Performance4.91%5.04%2.78%10.09%
1 Year Performance-69.50%97.30%15.85%115.85%

Physiomics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PYC
Physiomics
N/AGBX 0.43
+0.5%
N/A-72.5%£876,000.00£864,071.75-0.9610
MTFB
Motif Bio
N/AN/AN/AN/A£3.28MN/A-0.036
DEST
Destiny Pharma
N/AN/AN/AN/A£2.87M£135,028.00-50.0024Gap Down
High Trading Volume
ROQ
Roquefort Therapeutics
N/AGBX 1.67
-10.0%
N/A-63.7%£2.12M£2,662.35-1.379Earnings Report
Negative News
VAL
ValiRx
N/AGBX 0.52
+8.8%
N/A-83.8%£1.96M£27,777.32-0.355,450Gap Down
RENE
ReNeuron Group
N/AN/AN/AN/A£1.93M£783,000.00-37.502Gap Down
NFX
Nuformix
2.1358 of 5 stars
GBX 0.14
+5.9%
GBX 293
+204,795.1%
-29.3%£1.76MN/A-4.343Gap Up
High Trading Volume
SALV
SalvaRx Group
N/AN/AN/AN/A£1.65M£64.50M0.032Gap Up
ONC
Oncimmune
N/AN/AN/AN/A£1.29M£1.86M0.1352
OVB
Ovoca Bio
N/AGBX 1.28
flat
N/A+80.0%£1.28MN/A-1.175
OCTP
Oxford Cannabinoid Technologies
N/AN/AN/AN/A£1.25MN/A-53.107Gap Down

Related Companies and Tools


This page (LON:PYC) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners